NG
SRPT icon

NWK Group’s Sarepta Therapeutics SRPT Stock Holding History

NWK Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-325
Closed -$55K – 209
2020
Q4 		$55K Hold
325
– – 0.02% 106
2020
Q3 		$46K Hold
325
– – 0.02% 103
2020
Q2 		$52K Hold
325
– – 0.03% 92
2020
Q1 		$32K Buy
325
+75
+30% +$8.57K 0.03% 101
2019
Q4 		$32K Buy
+250
New +$25.2K 0.03% 122

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

NWK Group's SRPT Position: Q1 2021 in Review

NWK Group sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 325 shares — an estimated $55K sold.

NWK Group first reported a position in SRPT in Q4 2019 and held it in 5 quarters. The position peaked at $55K in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

  • NWK Group reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
  • NWK Group sold 325 Sarepta Therapeutics shares in Q1 2021, an estimated $55K.
  • NWK Group first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 5 quarters.
  • NWK Group's Sarepta Therapeutics position peaked at $55K in Q4 2020.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on NWK Group's 13F filing for Q1 2021, filed 14 May 2021.